Xortx Therapeutics Inc. - Understand $xrtx stock

$XRTX Market Cap: $8.101 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$1.483M

TTM

Current Assets

$3.357M

Q2 2024

Current Liabilities

$2.095M

Q2 2024

Current Ratio

160.25%

Q2 2024

Total Assets

$4.799M

Q2 2024

Total Liabilities

$2.095M

Q2 2024

Book Value

$2.705M

Q2 2024

Cash

$3.011M

Q2 2024

P/E

-5.462

Nov 29, 2024 EST

Free Cash Flow

-$4.438M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$814.3M	$38.95M	$1.448B	$1.602B
YoY Change									1990.68%	-97.31%	-9.58%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$814.3M	$38.95M	$1.448B	$1.602B
Cost Of Revenue									$643.2M	$963.1M	$1.226B	$1.322B
Gross Profit									$171.1M	$195.8M	$222.1M	$279.8M
Gross Profit Margin									21.01%	502.8%	15.33%	17.47%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Selling, General & Admin	$3.488M	$4.502M	$2.779M	$1.098M	$506.2K	$795.7K	$380.9K	$193.5K	$69.47M	$57.88M	$66.38M	$60.00M
YoY Change	-22.53%	62.02%	153.03%	116.94%	-36.38%	108.88%	96.83%		20.02%	-12.81%	10.63%
% of Gross Profit									40.61%	29.55%	29.89%	21.45%
Research & Development	$2.419M	$8.808M	$853.1K	$277.5K	$39.90K	$342.3K	$66.37K		$98.10M	$101.4M	$115.6M	$92.70M
YoY Change	-72.54%	932.44%	207.47%	595.39%	-88.34%	415.67%			-3.23%	-12.28%	24.66%
% of Gross Profit									57.34%	51.76%	52.04%	33.13%
Depreciation & Amortization	$139.7K	$75.27K	$17.88K	$20.44K	$19.90K	$19.32K	$16.78K		$17.82M	$7.510M	$23.59M	$22.11M
YoY Change	85.59%	320.97%	-12.52%	2.71%	3.0%	15.14%			137.28%	-68.16%	6.69%
% of Gross Profit									10.42%	3.83%	10.62%	7.9%
Operating Expenses	$6.046M	$13.39M	$3.650M	$1.396M	$566.0K	$1.157M	$464.1K	$193.5K	$169.6M	-$736.6M	$186.1M	$156.4M
YoY Change	-54.83%	266.76%	161.43%	146.65%	-51.09%	149.36%	139.79%		-123.03%	-495.81%	19.02%
Operating Profit									$1.460M	$932.5M	$35.96M	$123.4M
YoY Change									-99.84%	2493.1%	-70.86%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Interest Expense	$3.888M	$5.157M	$3.621M	-$9.710K	-$61.98K	$22.00K	-$4.760K		$260.0K	$7.380M	$390.0K	$40.00K
YoY Change	-24.62%	42.44%	-37390.63%	-84.33%	-381.73%	-562.18%			-96.48%	1792.31%	875.0%
% of Operating Profit									17.81%	0.79%	1.08%	0.03%
Other Income/Expense, Net	$0.00	-$1.258M	-$1.624M	-$850.00	-$1.640K	-$1.920K	-$5.380K	-$230.5K		-$40.00K
YoY Change	-100.0%	-22.54%	190921.18%	-48.17%	-14.58%	-64.31%	-97.67%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Pretax Income	-$2.158M	-$9.485M	-$1.652M	-$1.285M	-$629.6K	-$3.776M	-$474.2K	-$424.1K	-$1.960M	-$180.1M	$31.37M	$123.4M
YoY Change	-77.25%	474.07%	28.62%	104.04%	-83.33%	696.27%	11.82%		-98.91%	-674.18%	-74.59%
Income Tax									$19.25M	$430.0K	$3.080M	-$15.99M
% Of Pretax Income											9.82%	-12.95%
Net Earnings	-$2.158M	-$9.485M	-$1.652M	-$1.285M	-$629.6K	-$3.776M	-$474.2K	-$424.1K	-$21.21M	-$180.6M	$28.30M	$139.4M
YoY Change	-77.25%	474.07%	28.62%	104.04%	-83.33%	696.27%	11.82%		-88.25%	-737.99%	-79.7%
Net Earnings / Revenue									-2.6%	-463.54%	1.95%	8.7%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.09	-$0.71	-$167.8K	-$192.8K	-$117.5K	-$717.1K	-$249.2K	-$299.4K	-$772.4K	-$3.584M	$923.9K	$4.459M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Cash & Short-Term Investments	$3.448M	$8.947M	$18.85M	$1.998M	$714.9K	$949.4K	$61.94K	$185.8K	$103.0M	$426.4M	$132.6M	$90.84M
YoY Change	-61.47%	-52.54%	843.66%	179.42%	-24.69%	1432.76%	-66.66%		-75.84%	221.46%	46.0%
Cash & Equivalents	$3.353M	$8.947M							$103.0M	$242.0M	$132.6M	$90.84M
Short-Term Investments			$0.00	$1.826M	$656.3K	$689.4K				$184.3M
Other Short-Term Assets	$560.4K	$5.692M	$1.271M	$0.00	$84.84K		$1.610K		$15.69M	$20.78M	$19.34M	$15.23M
YoY Change	-90.16%	348.02%		-100.0%					-24.49%	7.45%	26.99%
Inventory									$132.2M	$171.6M	$164.2M	$195.9M
Prepaid Expenses
Receivables	$60.71K	$110.7K	$51.54K	$58.47K	$15.47K	$30.26K		$0.00	$90.83M	$15.29M	$200.7M	$209.0M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.069M	$14.75M	$20.17M	$2.056M	$815.3K	$979.7K	$63.55K	$185.8K	$341.7M	$455.1M	$516.9M	$511.1M
YoY Change	-72.42%	-26.88%	881.13%	152.21%	-16.78%	1441.54%	-65.79%		-24.91%	-11.96%	1.14%
Property, Plant & Equipment	$23.93K	$125.5K		$0.00	$340.00	$730.00	$1.120K	$5.000K	$41.59M	$17.61M	$45.22M	$45.69M
YoY Change	-80.94%			-100.0%	-53.42%	-34.82%	-77.6%		136.17%	-61.06%	-1.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.200M	$1.606M	$1.606M							$25.92M
YoY Change	-25.3%	0.0%
Other Assets							$167.2K		$6.580M	$4.820M	$13.48M	$14.91M
YoY Change									36.51%	-64.24%	-9.59%
Total Long-Term Assets	$1.399M	$2.003M	$1.863M	$234.3K	$272.7K	$285.6K	$427.1K	$5.000K	$62.46M	$83.30M	$76.82M	$69.92M
YoY Change	-30.13%	7.51%	694.88%	-14.08%	-4.5%	-33.12%	8441.0%		-25.02%	8.44%	9.87%
Total Assets	$5.468M	$16.75M	$22.04M	$2.290M	$1.088M	$1.265M	$490.6K	$190.8K	$404.2M	$538.4M	$593.7M	$581.0M
YoY Change
Accounts Payable	$195.8K	$1.758M	$410.7K	$1.034M	$607.4K	$798.1K	$778.7K	$13.55K	$67.06M	$6.240M	$168.7M	$155.8M
YoY Change	-88.86%	328.17%	-60.29%	70.27%	-23.9%	2.5%	5646.72%		974.68%	-96.3%	8.29%
Accrued Expenses	$87.61K	$202.3K	$290.3K		$544.1K				$35.78M	$38.97M	$48.10M	$39.17M
YoY Change	-56.68%	-30.33%							-8.19%	-18.98%	22.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.51K	$105.1K		$0.00	$50.81K		$236.7K			$20.00K
YoY Change	-89.05%			-100.0%
Total Short-Term Liabilities	$294.9K	$2.066M	$701.0K	$1.034M	$1.300M	$900.5K	$1.109M	$13.55K	$109.4M	$85.67M	$224.5M	$213.7M
YoY Change	-85.72%	194.7%	-32.22%	-20.43%	44.34%	-18.84%	8087.97%		27.66%	-61.84%	5.09%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$43.26K	$35.77K	$0.00		$120.0K
YoY Change					-100.0%	20.94%
Other Long-Term Liabilities	$531.0K	$5.221M	$4.597M							$41.49M
YoY Change	-89.83%	13.56%
Total Long-Term Liabilities	$531.0K	$5.221M	$4.597M	$0.00	$0.00	$43.26K	$35.77K	$0.00		$41.61M
YoY Change	-89.83%	13.56%			-100.0%	20.94%
Total Liabilities	$825.9K	$7.287M	$5.298M	$1.034M	$1.300M	$943.7K	$1.145M	$13.55K	$109.4M	$128.4M	$224.5M	$213.7M
YoY Change	-88.66%	37.52%	412.31%	-20.43%	37.72%	-17.6%	8351.96%		-14.85%	-42.79%	5.09%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2013	2012	2011	2010
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $8.1009 Million

About XORTX Therapeutics Inc.

XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. The company is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The firm has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The firm's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Industry: Pharmaceutical Preparations Peers: Lucy Scientific Discovery, Inc.